The following information was compiled in August 2024 and is subject to change as new research is conducted and as new information becomes available:

Description: Bromantane is a novel stimulant described as an actoprotector and psychostimulant with structural similarity to adamantane and memantine.1 Bromantane was first synthesized for therapeutic use in Russia in the 1980s and has been used as a performance-enhancing drug.2 Bromantane was first detected in October 2023 by our laboratory and confirmed in March 2024 after acquiring standard reference material.

Sample Source: Oakland County Medical Examiner (Pontiac, MI)

Sample Appearance: Blood specimen

Pharmacology: Bromantane acts on the GABA receptors to strengthen GABA-inergic mediation and inhibits serotonin and dopamine reuptake.1

Toxicology: Bromantane has been identified in one toxicology case to date at the CFSRE.

Drug Materials: Bromantane has not been detected in drug materials to date at the CFSRE.

Demographics / Geographics: Toxicology cases originated from Michigan. Bromantane was found alongside novel benzodiazepines (e.g., bromazolam) and traditional stimulants (e.g., methamphetamine).

Legal Status: Bromantane is not currently scheduled in the United States.

Class: Stimulant
 Appearance: Blood
 Formula: C16H20BrN
 MW: 306.2  [M+]: 305  [M+H]+: 306.0852
 IUPAC: N-(4-bromophenyl)adamantan-2-amine
 Report Date: August 20, 2024